Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR

Lung Cancer. 2020 Oct;148:170-172. doi: 10.1016/j.lungcan.2020.07.002. Epub 2020 Jul 3.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma of Lung* / drug therapy
  • Adenocarcinoma of Lung* / genetics
  • Afatinib / therapeutic use
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Protein Kinase Inhibitors
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors